Full-Time

Manager – Clinical Data Management

CRISPR Therapeutics

CRISPR Therapeutics

201-500 employees

Develops gene-editing therapies using CRISPR

Compensation Overview

$123k - $133k/yr

+ Bonus + Equity

Boston, MA, USA

Hybrid

Hybrid role; at least 3 days on-site weekly.

Category
Data & Analytics (1)
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s degree in a health-related field is required.
  • Master’s degree strongly preferred
  • Minimum of 7+ years of progressive experience in clinical data management in a regulatory environment.
  • Demonstrated proficiency managing the lifecycle of clinical data projects.
  • Experience developing reports using J-Review, Business Objects, or other CDM reporting tools.
  • Experience with EDC databases, especially Medidata Rave.
  • Experience with CDASH/SDTM/CDISC standards.
  • Experience working with central and specialty labs/vendors.
  • Working knowledge of medical terminology and medical coding dictionaries including MedDRA and WHO.
  • Familiarity with GCP, ICH and FDA requirements as applicable for Clinical Data Management.
  • Ability to manage multiple initiatives and shifting priorities within a small, fast paced company environment.
  • Strong analytical and problem-solving skills that meet or improve the status quo.
  • Excellent interpersonal skills with the ability to work independently and collaboratively in a dynamic team environment.
  • Excellent written and oral communication skills.
Responsibilities
  • Plan, coordinate, and manage data management tasks and timelines.
  • Act as primary liaison with CROs, third party data vendors, and EDC vendors.
  • Collaborate with internal clinical study team to ensure all stakeholders’ needs are addressed.
  • Primary author/approver for CRFs, CCGs, edit check specifications, SAE reconciliation plans, Coding plans, Data Management Plans, and third party vendor data specifications.
  • Oversee database design, production and UAT cycles, ensuring that the CRO meets the highest quality standards.
  • Accountable for external data vendor documentation, management, and reconciliation.
  • Contribute to departmental SOP and process development and improvement, and integration of technology.
  • Perform and/or review medical coding and SAE reconciliation.
  • Support internal review/QC of clinical data.
  • Support GCP inspection readiness.
Desired Qualifications
  • Prior experience working in a small or medium-sized biotech or pharmaceutical company.

CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 to treat serious diseases. It edits genes in human cells, either ex vivo or in vivo, to correct disease-causing mutations, focusing on sickle cell disease, cancer, and other genetically defined conditions. The company supports its pipeline through partnerships and licensing in addition to internal R&D and clinical work, rather than relying solely on in-house development. Its goal is to deliver durable, disease-modifying therapies that meet unmet medical needs for patients worldwide through a global biopharmaceutical strategy.

Company Size

201-500

Company Stage

IPO

Headquarters

Switzerland

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Pediatric CASGEVY expansion targets ages 5–11, widening the addressable hemoglobinopathy market.
  • CTX310 and CTX611 create second and third commercial shots beyond CASGEVY.
  • A $2.44 billion cash balance funds multiple milestones without near-term financing pressure.

What critics are saying

  • CASGEVY remains the only commercial product, creating severe revenue concentration risk.
  • Vertex controls exa-cel manufacturing and licensing, limiting CRISPR's commercial control.
  • Unproven pipeline assets face binary trial and regulatory outcomes over the next 12–24 months.

What makes CRISPR Therapeutics unique

  • First approved CRISPR therapy, CASGEVY, is commercialized with Vertex Pharmaceuticals.
  • Pipeline spans HSC editing, autoimmune disease, CAR-T, diabetes, and cardiovascular programs.
  • In vivo delivery efforts aim to bypass ex vivo transplant workflows.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CRISPR Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Hybrid Work Options

Stock Options

401(k) Retirement Plan

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Paid Vacation

Paid Holidays

Relocation Assistance

Sabbatical Leave

Paid Sick Leave

Employee Discounts

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Meal Benefits

Commuter Benefits

Legal Services

Research Collaboration Benefits

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

1%
CRISPR Therapeutics
May 6th, 2026
CRISPR Therapeutics to present at the Bank of America Securities 2026 Global Healthcare Conference.

CRISPR Therapeutics to present at the Bank of America Securities 2026 Global Healthcare Conference. ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) - CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY(R)(exagamglogene autotemcel [exa-cel]), the world's first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase(TM) editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

Intellectia.AI
Mar 24th, 2026
CRISPR Raises $600 Million, Stock Price Pressured

- **Funding Details**: CRISPR completed a private offering of convertible senior notes, raising net proceeds of $585.2 million, which, while intended ...

Yahoo Finance
Mar 20th, 2026
CRISPR Therapeutics' CASGEVY patient initiations triple as $584M loss persists

CRISPR Therapeutics has reported strong commercial progress for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company plans to submit a regulatory application in the first half of 2026 to expand CASGEVY's approval to paediatric patients. The company's cardiovascular candidate CTX310 showed positive early clinical data, published in the New England Journal of Medicine, and is advancing into Phase 1b trials. CASGEVY is already commercially available, marking the company's transition from development to approved therapy. Despite the clinical progress, CRISPR Therapeutics remains unprofitable with a net loss of $581.6 million and limited revenue of approximately $3.5 million. The share price trades around 44% below analyst consensus targets, reflecting ongoing execution risk around trials and regulatory approvals.

Yahoo Finance
Mar 11th, 2026
CRISPR Therapeutics reports $116M revenue as CASGEVY patient initiations triple

CRISPR Therapeutics reported $116 million in revenue for fiscal year 2025, driven by its gene-editing therapy CASGEVY. The company generated $54 million in Q4 alone, with patient initiations increasing nearly threefold year-on-year. To date, 147 patients have begun treatment for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe and the Middle East. The company is advancing its in vivo liver editing portfolio, including CTX310 for cardiovascular conditions and CTX460 for alpha-1 antitrypsin deficiency, expected to enter clinical trials mid-2026. CRISPR is also collaborating with Sirius Therapeutics on thromboembolic disease treatments, with Phase 2 data for its lead Factor XI candidate anticipated in the second half of 2026.

Yahoo Finance
Mar 11th, 2026
CRISPR Therapeutics raises $350M via convertible notes as shares trade 38% below analyst targets

CRISPR Therapeutics has announced a $350 million offering of convertible senior notes to fund general corporate purposes, including pipeline development and commercialisation efforts. The gene editing therapy company currently trades at $52.80, approximately 38% below analysts' consensus target of $84.78. The convertible debt offering provides capital without immediate equity dilution, though conversion terms could affect the company's current 96 million share count. CRISPR Therapeutics generated only $4 million in revenue whilst posting ongoing losses, raising concerns about potential future dilution if pipeline development does not progress as planned. The company's shares have shown recent momentum with an 8.3% gain over 30 days. According to Simply Wall St's valuation model, shares trade 72.2% below estimated fair value.